Regular PPIs use increases rheumatoid arthritis risk in women

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-07-14 11:11 GMT | Update On 2020-07-15 10:15 GMT

Delhi: Regular use of proton pump inhibitors (PPIs) increases the risk of rheumatoid arthritis (RA) with a higher risk observed in individuals with a longer duration of PPI use, according to a recent study in the journal Alimentary Pharmacology & Therapeutics.

PPIs are among the most commonly prescribed medications used worldwide. It is used for a variety of acid-related disorders such as peptic ulcer disease, non-ulcer dyspepsia, and gastroesophageal reflux disease. However, long-term use of PPIs has been linked with a variety of health problems. Previous studies have shown PPIs to have a significant impact on the gut microbiome, which in turn, might increase the risk of RA.

Yihang Pan, the Precision Medicine Center at The Seventh Affiliated Hospital, China, and colleagues evaluated the association between regular use of PPIs and RA risk.

For the purpose, the researchers conducted a prospective analysis of the US nurses who reported PPI use data from the Nurses' Health Study (NHS 2002‐2014) and NHS II (2003‐2015), and were free from RA. The exposure was regular PPI use in the past 2 years. RA was confirmed by the 1987 or 2010 American College of Rheumatology criteria.

Key findings of the study include:

421 cases of RA were documented over 1 753 879 person‐years of follow‐up.
Regular PPI users had a 44% higher risk of RA as compared with non‐regular users (adjusted HR = 1.44).
The risk of RA increased with the total duration of PPI use.
Compared with non‐regular users, the adjusted HRs were 1.22 for women with >0 to 4 years' use and 1.73 for >4 years' use.

"Regular use of PPI was associated with increased risk of RA in women, with a higher risk observed in individuals with a longer duration of PPI use. Due to the observational study design, large prospective trials are still required to confirm our finding," concluded the authors.

The study, "Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study," is published in the journal Alimentary Pharmacology & Therapeutics.

DOI: https://doi.org/10.1111/apt.15834

Article Source : journal Alimentary Pharmacology & Therapeutics

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Regular PPIs use increases rheumatoid arthritis risk in women

Similar News

Delayed Hip Fracture Surgery Increases 30-Day Mortality in Older Adults, finds study

Muscular TMD tied to greater difficulty in Mastication compared to those without TMD: Study

Common arthritis drug reveals hidden benefit, suggests research

X-rays Effectively Clear Most Pediatric Cervical Spine Injuries, 10-Year Trauma Center Study Finds

People who skip breakfast and eat late dinners may have a higher risk of osteoporosis: Study

Gout Significantly Impairs Hand Function, Comparable to Rheumatoid Arthritis, suggests study

Unichem Pharma USA recalls one lot of Cyclobenzaprine Hydrochloride Tablets 10 mg over mislabeling

Osteoarthritis Linked to Increased Risk of Sleep Apnea, Study Finds